miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas
Angélique Gougelet1, Jennifer Perez, Daniel Pissaloux
1Unité INSERM U590 équipe Cytokines et Cancer, Centre Léon Bérard, 28 rue Laennec, 69373 Lyon cedex 08, France.
Abstract:
Sarcomas are divided into a group with specific alterations and a second presenting a complex karyotype, sometimes difficult to diagnose or with few therapeutic options available. We assessed if miRNA profiling by TaqMan low density arrays could predict the response of undifferentiated rhabdomyosarcoma (RMS) and osteosarcoma to treatment. We showed that miRNA signatures in response to a therapeutic agent (chemotherapy or the mTOR inhibitor RAD-001) were cell and drug specific on cell lines and a rat osteosarcoma model. This miRNA signature was related to cell or tumour sensitivity to this treatment and might be not due to chromosomal aberrations, as revealed by a CGH array analysis of rat tumours. Strikingly, miRNA profiling gave promising results for patient rhabdomyosarcoma, discriminating all types of RMS: (Pax+) or undifferentiated alveolar RMS as well as embryonal RMS. As highlighted by these results, miRNA profiling emerges as a potent molecular diagnostic tool for complex karyotype sarcomas.
Insights
MicroRNA (miRNA) profiling can predict sarcoma treatment response. This molecular tool shows promise for diagnosing complex sarcomas, including rhabdomyosarcoma, aiding therapeutic decisions.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Sarcomas are challenging cancers, often with complex genetic alterations.
- Diagnosis and treatment selection for sarcomas can be difficult due to heterogeneity.
- MicroRNAs (miRNAs) are small non-coding RNAs with regulatory roles in cancer.
Purpose of the Study:
- To investigate miRNA profiling as a predictive tool for sarcoma treatment response.
- To assess if miRNA signatures can differentiate sarcoma subtypes and predict therapeutic sensitivity.
- To evaluate miRNA profiling for diagnosing complex karyotype sarcomas.
Main Methods:
- Utilized TaqMan low-density arrays for miRNA profiling.
- Tested cell lines and a rat osteosarcoma model with chemotherapy and an mTOR inhibitor.
- Performed comparative genomic hybridization (CGH) array analysis on rat tumors.
- Applied miRNA profiling to patient rhabdomyosarcoma samples.
Main Results:
- miRNA signatures were cell- and drug-specific in response to treatment.
- Identified a correlation between miRNA signatures and treatment sensitivity.
- Found that miRNA signatures were independent of chromosomal aberrations.
- Successfully discriminated all rhabdomyosarcoma subtypes using miRNA profiling.
Conclusions:
- miRNA profiling is a potent molecular diagnostic tool for sarcomas.
- This approach can predict treatment response in rhabdomyosarcoma and osteosarcoma.
- miRNA signatures offer a novel method for classifying complex karyotype sarcomas.
More Related Videos
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019